Dr. Lal Path Labs share price
NSE: LALPATHLABBSE: 539524Healthcare ServicesSmall Cap
Dr. Lal Path Labs Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2015
Last close ₹1,922.30up ₹20.50 (1.08%)BSE ₹1,920.75
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,901.80.
28 Oct: open ₹1,885.20, high ₹1,936.50, low ₹1,871.00
52-week range of traded prices to 28 Oct 2026
₹1,272.60Low, 23 Mar 2026₹2,038.60High, 16 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results, other business matters and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹32,266 Cr309th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 59.54
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 12.86
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.83%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 23.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 26.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,24,17959.9% delivered
About Dr. Lal Path Labs
Dr. Lal PathLabs Limited runs a nationwide network of pathology and radiology laboratories in India, offering diagnostic and related healthcare tests used to diagnose, prevent, monitor and treat disease.12 It serves individual patients, hospitals, other healthcare providers and corporates through its laboratories, collection centres and home collection.134
Its specialty brands are Genevolve for genomics, L-CoRD for reproductive diagnostics and L-ACE for autoimmune disorders, alongside SwasthFit bundled preventive health checks and Sovaaka, an AI-powered precision health screening platform.56 Its national reference laboratory is in Delhi, with regional reference laboratories in Kolkata, Bengaluru and Mumbai.5 Outside India it has a presence in Nepal and Bangladesh.7
S. K. Lal founded the business in New Delhi in 1949; the company was incorporated in 1995 and listed on the stock exchanges through an initial public offering in December 2015.89 It acquired Suburban Diagnostics in 2021; Suburban's business passed to the company on 18 Mar 2025 during Suburban's voluntary liquidation, and the National Company Law Tribunal ordered the former subsidiary dissolved on 27 Feb 2026.101112 The Suburban business, run under the Suburban brand, is the company's main business in West India.13
Its promoter and promoter group held 53.19% of the shares at the end of June 2026.14 Arvind Lal, its Executive Chairman, is a promoter director.1516
Dr. Lal Path Labs key points
Results
- In the quarter to Jun 2026, revenue rose 19.1% to ₹798 crore from ₹670 crore, its highest quarterly growth rate in 4 years. EBITDA (earnings before interest, tax, depreciation and amortisation) rose 28.7% to ₹247 crore from ₹192 crore, a 31.0% EBITDA margin.1718
- Profit after tax in the quarter to Jun 2026 rose 27.2% to ₹170 crore from ₹134 crore, a profit after tax margin (profit as a share of revenue) of 21.4%. Net cash and equivalents were ₹1,693 crore at 30 Jun 2026.19
- In the year to Mar 2026, consolidated revenue rose 12.2% to ₹27,629 million from ₹24,614 million, and reported profit after tax rose 3.6% to ₹5,098 million from ₹4,922 million; the earlier year included a one-time tax benefit from Suburban's liquidation.2021
- Reported EBITDA for the year to Mar 2026 was ₹7,524 million after a one-time charge of ₹301 million for the new Labour Code; excluding that charge, EBITDA was ₹7,825 million, up 12.5%.22
Revenue mix
- Sales directly to patients (B2C) make up about 75% of revenue and sales through hospitals, laboratories and other businesses (B2B) about 25%, as in the quarter to Jun 2026.23
- On its earnings call of 24 Jul 2026, the company said SwasthFit bundled health checks are 27% of its revenue, and that SwasthFit grew about 20% in the quarter to Jun 2026.2425
- Tier 3+ markets (smaller cities, towns and rural areas) contributed 39% of revenue in the year to Mar 2026.26
- Revenue per patient rose 10% to ₹968 from ₹880 in the quarter to Jun 2026, on test and geography mix and higher prices under the CGHS and ECHS government health schemes, a benefit the company puts at 2% to 3% at company level.272829
Where revenue comes from
- Share of consolidated revenue by region30
Item year to Mar 2026 year to Mar 2025 Delhi NCR 31% 31% Uttar Pradesh and Uttarakhand 19% 19% East India 15% 14% West India 14% 15% Rest of North India 13% 13% South India 6% 6% Others 2% 2%
Laboratory and collection network
- At 31 Mar 2026 the company had 312 clinical laboratories, 7,727 patient service centres (centres where patients give samples) and 13,935 pick-up points where samples are collected.31
- It tested 94.5 million samples from 30.3 million patients in the year to Mar 2026, against 85.6 million samples from 28.8 million patients a year earlier.32
- In the quarter to Jun 2026, patient volume grew 8.2% to 8.2 million and sample volume grew 10.7% to 25.9 million.33
Research and development
What the company expects
- On its earnings call of 24 Jul 2026, the company said it plans to add 12 to 15 laboratories in the year to Mar 2027, and possibly 3 to 4 radiology centres.36
- On its earnings call of 24 Jul 2026, the company said it had guided for patient volume growth of 6% to 7% in the year to Mar 2027, to be reviewed after the first half.37
- On its earnings call of 24 Jul 2026, the company said its capital spending is roughly ₹140 crore to ₹150 crore and that acquisitions would be the main use of its cash.38
- On its earnings call of 24 Jul 2026, the company said it sees international growth over a 3 to 5 year horizon, focused on Africa, the Middle East, CIS countries (former Soviet states) and Southeast Asia, with no target yet set.3940
Recent events
- In its exchange filing of 26 Sep 2026, the company said its Dubai subsidiary, formed on 12 Jun 2026, had completed the purchase of 80% of Sunshine Healthcare Limited in Ghana, which became a step-down subsidiary (a subsidiary of a subsidiary).4142
- On 24 Sep 2026 the board approved buying 70% of SN Genelab Private Limited, a genomics diagnostics business with turnover of ₹57.96 crore in the year to Mar 2026, for up to ₹168 crore plus an earn-out (a performance-linked extra payment) capped at ₹31.5 crore.434445
- On 1 May 2026 the company bought 100% of Shahbazkers Diagnostic Centre Private Limited, a diagnostics and healthcare services provider, for ₹200 million in cash.46
- On 22 Dec 2025 the company allotted 8,37,75,510 bonus shares in a 1:1 bonus issue (1 free share for every share held).47
Litigation and regulatory matters
- In its exchange filing of 17 Jul 2026, the company said the income tax appeals authority had allowed its appeal against an assessment order dated 31 Mar 2024, and allowed a deduction of ₹32,66,18,927 for employee stock option expenses.48
Last updated
All 48 sources, each with its page
- 1. Investor presentation, 24 Jul 2026, page 29
- 2. Annual report, 1 Jul 2026, page 337
- 3. Investor presentation, 24 Jul 2026, page 22
- 4. Annual report, 1 Jul 2026, page 13
- 5. Annual report, 1 Jul 2026, page 128
- 6. Annual report, 1 Jul 2026, page 26
- 7. Earnings call, 24 Jul 2026, page 4
- 8. Investor presentation, 24 Jul 2026, page 21
- 9. Annual report, 1 Jul 2026, page 9
- 10. Annual report, 1 Jul 2026, page 10
- 11. Annual report, 1 Jul 2026, page 102
- 12. Annual report, 1 Jul 2026, page 120
- 13. Earnings call, 24 Jul 2026, page 11
- 14. Investor presentation, 24 Jul 2026, page 15
- 15. Annual report, 1 Jul 2026, page 12
- 16. Annual report, 1 Jul 2026, page 190
- 17. Earnings call, 24 Jul 2026, page 5
- 18. Earnings call, 24 Jul 2026, page 4
- 19. Earnings call, 24 Jul 2026, page 6
- 20. Annual report, 1 Jul 2026, page 130
- 21. Annual report, 1 Jul 2026, page 16
- 22. Annual report, 1 Jul 2026, page 16
- 23. Earnings call, 24 Jul 2026, page 17
- 24. Earnings call, 24 Jul 2026, page 18
- 25. Earnings call, 24 Jul 2026, page 8
- 26. Annual report, 1 Jul 2026, page 24
- 27. Earnings call, 24 Jul 2026, page 5
- 28. Earnings call, 24 Jul 2026, page 9
- 29. Earnings call, 24 Jul 2026, page 7
- 30. Annual report, 1 Jul 2026, page 130
- 31. Investor presentation, 24 Jul 2026, page 29
- 32. Investor presentation, 24 Jul 2026, page 29
- 33. Earnings call, 24 Jul 2026, page 4
- 34. Annual report, 1 Jul 2026, page 132
- 35. Earnings call, 24 Jul 2026, page 4
- 36. Earnings call, 24 Jul 2026, page 10
- 37. Earnings call, 24 Jul 2026, page 7
- 38. Earnings call, 24 Jul 2026, page 21
- 39. Earnings call, 24 Jul 2026, page 20
- 40. Earnings call, 24 Jul 2026, page 10
- 41. Exchange filing, 26 Sep 2026, page 1
- 42. Exchange filing, 24 Jul 2026, page 6
- 43. Exchange filing, 24 Sep 2026, page 1
- 44. Exchange filing, 24 Sep 2026, page 2
- 45. Exchange filing, 24 Sep 2026, page 2
- 46. Exchange filing, 24 Jul 2026, page 6
- 47. Annual report, 1 Jul 2026, page 102
- 48. Exchange filing, 17 Jul 2026, page 2
Results
Consolidated; ₹ crore.Dr. Lal Path Labs quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +14.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +5.6%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹798 Crup 13.52%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹171 Crup 28.97%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 21.4%
Revenue by quarter
Peak revenue ₹798 Cr, quarter to Jun 2026; lowest ₹597 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 660 | 597 | 603 | 670 | 731 | 660 | 703 | 798 |
| Net profit | 131 | 98 | 156 | 134 | 152 | 91 | 132 | 171 |
| Net margin | 19.8% | 16.4% | 25.8% | 20.0% | 20.8% | 13.9% | 18.8% | 21.4% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2,763 Crup 12.25%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹510 Crup 3.58%
- Net margin
- 18.5%
Revenue by year
Peak revenue ₹2,763 Cr, year to Mar 2026; lowest ₹912 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 912 | 1,057 | 1,203 | 1,330 | 1,581 | 2,087 | 2,017 | 2,227 | 2,461 | 2,763 |
| Net profit | 154 | 172 | 201 | 228 | 297 | 350 | 241 | 362 | 492 | 510 |
| Net margin | 16.9% | 16.3% | 16.7% | 17.1% | 18.8% | 16.8% | 12.0% | 16.3% | 20.0% | 18.5% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment which carries all its revenue.
Valuation
Today, against the company's own history.Dr. Lal Path Labs PE ratio and valuation
Price to earnings
At or below today's level on 58% of 2,467 trading days since Nov 2016.
LowestHighest
Its median56.46Industry median18.89
Price to book
At or below today's level on 63% of 1,976 trading days since Nov 2018.
LowestHighest
Its median12.25Industry median1.58
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 83% of 2,474 trading days over the last 10 years.
LowestHighest
Its median0.55%Industry median0.36%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +6.9% | +3.4% | +2.4% | 1.1% |
| 3 years | +13.8% | +28.0% | −11.9% | 1.0% |
| 5 years | +0.2% | +11.4% | −10.8% | 0.8% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
158 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 59 of the 80 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 158 funds holding Dr. Lal Path Labs
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 37
- CutCut. Funds that held fewer shares than at the end of the month before.
- 43
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 73
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 3
| Fund | |||
|---|---|---|---|
 HDFC Flexi Cap FundHDFC Mutual Fund | 41,78,451 | 0.76% | ₹830.3 Cr |
 UTI Flexi Cap FundUTI Mutual Fund | 25,15,829 | 2.22% | ₹499.9 Cr |
 Aditya Birla Sun Life Flexi Cap FundAditya Birla Sun Life Mutual Fund | 23,50,000 | 1.67% | ₹466.9 Cr |
 SBI Large & Midcap FundSBI Mutual Fund | 13,00,000 | 0.64% | ₹258.3 Cr |
 Nippon India Small Cap FundNippon India Mutual Fund | 12,90,970 | 0.32% | ₹256.5 Cr |
 Sundaram Mid Cap FundSundaram Mutual Fund | 11,75,000 | 1.69% | ₹233.5 Cr |
| Nippon India Multi Cap FundNippon India Mutual Fund | 11,46,484 | 0.42% | ₹227.8 Cr |
| HDFC ELSS - Tax Saver FundHDFC Mutual Fund | 11,40,000 | 1.52% | ₹226.5 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 10,00,578 | 2.17% | ₹198.8 Cr |
| HDFC Retirement Fund - EquityHDFC Mutual Fund | 7,00,000 | 2.09% | ₹139.1 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Dr. Lal Path Labs insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group0 purchases, 1 saleNo purchase₹61 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹61 Cr
- Directors and key managers0 purchases, 5 salesNo purchase₹4.91 CrNet−₹4.91 Cr4 off-market moves
- Employees0 purchases, 1 saleNo purchase₹0.25 CrNet−₹0.25 Cr1 pledge created · 7 off-market moves
- Others0 purchases, 62 salesNo purchase₹15 CrNet−₹15 Cr5 pledge filings of unclear kind · 76 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Dr. Lal Path Labs competitors and peers
Healthcare Service Provider, 37 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Dr. Lal Path Labs in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Vijaya Diagnostic CentreVIJAYA | 14,861 | 79.26 | 15.53 | +20.2% | +24.9% | 21.4% | 27.8% | 0.14% |
 Metropolis HealthcareMETROPOLIS | 11,435 | 56.71 | 7.56 | +21.8% | +32.6% | 14.2% | 18.6% | 0.36% |
 Thyrocare TechnologiesTHYROCARE | 7,871 | 44.64 | 13.44 | +21.1% | +65.7% | 31.1% | 37.9% | 1.42% |
 Nephrocare Health ServicesNEPHROPLUS | 6,319 | – | 5.66 | – | – | – | – | 0.00% |
 Suraksha DiagnosticSURAKSHA | 1,623 | 45.35 | 6.63 | +23.3% | +8.1% | 15.7% | 24.0% | 0.16% |
 Krsnaa DiagnosticsKRSNAA | 1,610 | 16.52 | 1.64 | +10.2% | +21.5% | 10.5% | 8.0% | 0.40% |
 3B Blackbio Dx3BBLACKBIO | 1,170 | 21.07 | 3.61 | +54.3% | +13.2% | 18.7% | 14.1% | 0.37% |
 One Global Service ProviderONEGLOBAL | 918 | 12.41 | 6.50 | +161.6% | +178.3% | 69.4% | 69.2% | 0.21% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dr. Lal Path Labs dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹14.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 30 Jul 2026 | Interim | ₹5.00 |
| 25 Jun 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹4.00 |
| 5 Feb 2026 | Interim | ₹3.50 |
| 7 Nov 2025 | Interim | ₹7.00 |
| 6 Aug 2025 | Interim | ₹6.00 |
| 6 Jun 2025 | Final | ₹6.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Dr. Lal Path Labs announcements
Oct 2026
13 Oct · General Updates
12 Oct · General Updates
8 Oct · General Updates
1 Oct · General Updates
Sep 2026
Dr. Lal Path Labs share price by year
Each calendar year to 2025.Dr. Lal Path Labs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,482.60 | −1.2% | 1,736.75 | 1,155.23 |
| 2024 | 1,500.20 | +16.4% | 1,802.78 | 1,005.53 |
| 2023 | 1,288.85 | +14.0% | 1,371.53 | 889.93 |
| 2022 | 1,130.23 | −40.9% | 1,930.65 | 917.98 |
| 2021 | 1,911.13 | +65.8% | 2,104.30 | 1,117.45 |
| 2020 | 1,152.63 | +54.3% | 1,161.33 | 625.98 |
| 2019 | 746.98 | +64.1% | 838.05 | 456.53 |
| 2018 | 455.15 | +3.3% | 539.48 | 403.55 |
| 2017 | 440.65 | −17.7% | 559.63 | 368.68 |
| 2016 | 535.48 | +33.1% | 623.98 | 360.18 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,848.00 | 1,913.90 | 1,821.30 | 1,901.80 | 1,881.31 | 2,73,785 | 66.1% |
| 26 Oct 2026 | 1,844.00 | 1,867.00 | 1,797.80 | 1,855.60 | 1,833.51 | 4,67,078 | 72.6% |
| 23 Oct 2026 | 1,839.00 | 1,854.60 | 1,801.20 | 1,838.20 | 1,832.33 | 1,19,250 | 56.6% |
| 22 Oct 2026 | 1,835.00 | 1,857.60 | 1,824.10 | 1,843.70 | 1,838.10 | 3,49,768 | 70.2% |
| 21 Oct 2026 | 1,843.70 | 1,873.10 | 1,819.90 | 1,836.10 | 1,850.86 | 2,91,322 | 75.7% |
| 19 Oct 2026 | 1,856.00 | 1,876.10 | 1,828.40 | 1,843.70 | 1,843.14 | 1,90,469 | 63.3% |
| 16 Oct 2026 | 1,880.00 | 1,907.90 | 1,851.90 | 1,859.90 | 1,871.66 | 2,45,047 | 66.1% |
| 15 Oct 2026 | 1,934.00 | 1,936.80 | 1,856.80 | 1,885.10 | 1,884.83 | 2,18,448 | 59.6% |
| 14 Oct 2026 | 1,910.60 | 1,942.00 | 1,887.10 | 1,938.00 | 1,913.47 | 2,23,891 | 51.7% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 19 Dec 2025 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- LALPATHLAB
- BSE code
- 539524
- ISIN
- INE600L01024
- Industry
- Healthcare Services
- Website
- www.lalpathlabs.com
- CIN
- L74899DL1995PLC065388
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1995
- Registered office
- Block E, Sector - 18, Rohini, New Delhi 110085, Delhi
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, Nifty Smallcap 100, BSE SmallCap